Chinook Therapeutics, Inc. Banner Image

Chinook Therapeutics, Inc.

  • Ticker KDNY
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Chinook Therapeutics, Inc. Logo Image
  • 201-500 Employees
  • Based in Seattle, Washington
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathyMore and proteinuric glomerular diseases. Zigakibart (BION-1301), an anti-APRIL monoclonal antibody, is being evaluated in a phase 1/2 trial for IgA nephropathy. CHK-336, an oral small molecule LDHA inhibitor for the treatment of hyperoxalurias, is in phase 1 development. In addition, Chinook’s research and discovery efforts are focused on building a pipeline of precision medicines for rare, severe chronic kidney diseases with defined genetic and molecular drivers. Chinook is leveraging insights from kidney single cell RNA sequencing and large CKD patient cohorts that have been comprehensively panomically phenotyped, with retained biosamples and prospective clinical follow-up, to discover and develop therapeutic candidates with mechanisms of action targeted against key kidney disease pathways.
4.8 / 5.0 (124)

Chinook Therapeutics, Inc. reports have an aggregate usefulness score of 4.8 based on 124 reviews.

Chinook Therapeutics, Inc.

Most Recent Annual Report

Chinook Therapeutics, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Chinook Therapeutics, Inc. does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.

Request Information

Older/Archived Annual Reports

Chinook Therapeutics, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!